Network pharmacology-based strategy for predicting active ingredients and potential targets of Yangxinshi tablet for treating heart failure

Journal of Ethnopharmacology

Volumn 219, Issue , 2018, Pages 359-368

  Chen, Langdong ^a   Cao, Yan ^a   Zhang, Hai ^b   Lv, Diya ^a   Zhao, Yahong ^c   Liu, Yanjun ^c   Ye, Guan ^c   Chai, Yifeng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Central Research Institute   (China)

Author keywords

Heart failure; Network pharmacology; Yangxinshi tablet

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; APIGENIN; ASTRAGALOSIDE I; ASTRAGALOSIDE III; CALYCOSIN; CARDIOVASCULAR AGENT; CHLOROGENIC ACID; DAIDZIN; FERULIC ACID; GENIPOSIDE; GINSENOSIDE; GINSENOSIDE RB 2; GINSENOSIDE RB 3; GINSENOSIDE RG 2; GINSENOSIDE RH 1; GINSENOSIDE RH 2; ICARIIN; ICARITIN; ISOASTRAGALOSIDE I; LIQUIRITIN; LUTEOLIN; PHYTOCHEMICAL; PLANT EXTRACT; PROTEIN; PUERARIN; QUERCETIN; RUTOSIDE; TETRAHYDROPALMATINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YANGXINSHI; HERBACEOUS AGENT;

ARTICLE; BIOINFORMATICS; CARDIOVASCULAR SYSTEM; DATA BASE; DRUG PROTEIN BINDING; DRUG TARGETING; GENETIC DATABASE; HEART FAILURE; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE SYSTEM; MOLECULAR DOCKING; PREDICTION; SURFACE PLASMON RESONANCE; TABLET; VIRTUAL REALITY; CHEMISTRY; CHINESE MEDICINE; DRUG DELIVERY SYSTEM; FORECASTING; PROCEDURES; PROTEIN SECONDARY STRUCTURE;

DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; FORECASTING; HEART FAILURE; HIGH-THROUGHPUT SCREENING ASSAYS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, SECONDARY; TABLETS;

EID: 85044629950     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2017.12.011     Document Type: Article

References (54)

1. Braz, J.C., Bueno, O.F., Liang, Q., Wilkins, B.J., Dai, Y.S., Parsons, S., Braunwart, J., Glascock, B.J., Klevitsky, R., Kimball, T.F., Hewett, T.E., Molkentin, J.D., Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Investig. 111 (2003), 1475–1486.
2. Chan, S.W., Hu, M., Tomlinson, B., The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure. Expert Opin. Drug Metab. Toxicol. 8 (2012), 767–790.
3. Demchak, B., Hull, T., Reich, M., Liefeld, T., Smoot, M., Ideker, T., Mesirov, J.P., Cytoscape: the network visualization tool for GenomeSpace workflows. F1000Research, 3, 2014, 151.
4. Feng, X., Yu, W., Li, X., Zhou, F., Zhang, W., Shen, Q., Li, J., Zhang, C., Shen, P., Apigenin, a modulator of PPARgamma, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation. Biochem. Pharmacol. 136 (2017), 136–149.
5. Fischer, M.J., Amine coupling through EDC/NHS: a practical approach. Methods Mol. Biol. 627 (2010), 55–73.
6. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P., Shenkin, P.S., Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J. Med. Chem. 47 (2004), 1739–1749.
7. Garg, R., Yusuf, S., Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor trials. Jama 273 (1995), 1450–1456.
8. Giannetti, A.M., Koch, B.D., Browner, M.F., Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem. 51 (2008), 574–580.
9. Hoang, V., Alam, M., Addison, D., Macedo, F., Virani, S., Birnbaum, Y., Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern Statin era: a meta-analysis of randomized-controlled trials. Cardiovasc. Drugs Ther. / Spons. Int. Soc. Cardiovasc. Pharmacother. 30 (2016), 189–198.
10. Hondeghem, L.M., Katzung, B.G., Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu. Rev. Pharmacol. Toxicol. 24 (1984), 387–423.
11. Hopkins, A.L., Network pharmacology. Nat. Biotechnol. 25 (2007), 1110–1111.
12. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (2008), 682–690.
13. Kamimura, D., Uchino, K., Ishigami, T., Hall, M.E., Umemura, S., Activation of peroxisome proliferator-activated receptor gamma prevents development of heart failure with preserved ejection fraction; inhibition of wnt-beta-catenin signaling as a possible mechanism. J. Cardiovasc. Pharmacol. 68 (2016), 155–161.
14. Kazi, D., Deswal, A., Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol. Clin. 26 (2008), 1–14.
15. Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Makela, S., Aittokallio, T., Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat. Product. Rep. 32 (2015), 1249–1266.
16. Kiss, K., Fekete, V., Paloczi, J., Sarkozy, M., Murlasits, Z., Pipis, J., Kheyfets, I.A., Dugina, J.L., Sergeeva, S.A., Epstein, O.I., Csonka, C., Csont, T., Ferdinandy, P., Bencsik, P., Renin-angiotensin-aldosterone signaling inhibitors-Losartan, enalapril, and Cardosten-prevent infarction-induced heart failure development in rats. Altern. Ther. Health Med. 22 (2016), 10–17.
17. Lau, J.M., Jin, X., Ren, J., Avery, J., DeBosch, B.J., Treskov, I., Lupu, T.S., Kovacs, A., Weinheimer, C., Muslin, A.J., The 14-3-3tau phosphoserine-binding protein is required for cardiomyocyte survival. Mol. Cell. Biol. 27 (2007), 1455–1466.
18. Li, C., Li, Q., Liu, R., Niu, Y., Pan, Y., Zhai, Y., Mei, Q., Medicinal herbs in the prevention and treatment of osteoporosis. Am. J. Chin. Med. 42 (2014), 1–22.
19. Li, Q., Huai, L., Zhang, C., Wang, C., Jia, Y., Chen, Y., Yu, P., Wang, H., Rao, Q., Wang, M., Wang, J., Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. Int. J. Hematol. 97 (2013), 617–623.
20. Li, S., Zhang, B., Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin. J. Nat. Med. 11 (2013), 110–120.
21. Li, Y., Yang, K., Shi, Q., Liu, B., Jin, Y., Liu, X., Jiang, Z., Luan, L., Wu, Y., Development of a method using high-performance liquid chromatographic fingerprint and multi-ingredients quantitative analysis for the quality control of Yangxinshi Pian. J. Sep. Sci. 38 (2015), 2989–2994.
22. Li, Y.F., Cao, F.F., Liu, F., Bai, X.Y., Lu, Y., Effects of Shexiangbaoxin pills on the expression of cardiac alpha(1)- and beta-adrenergic receptor subtypes in rat hearts with heart failure induced by myocardial infarction. Chin. Med. J. 125 (2012), 1556–1562.
23. Liu, H., Xiong, Y., Zhu, X., Gao, H., Yin, S., Wang, J., Chen, G., Wang, C., Xiang, L., Wang, P., Fang, J., Zhang, R., Yang, L., Icariin improves osteoporosis, inhibits the expression of PPARgamma, C/EBPalpha, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp. Ther. Med. 13 (2017), 1360–1368.
24. Liu, H.T., He, J.L., Li, W.M., Yang, Z., Wang, Y.X., Yin, J., Du, Y.G., Yu, C., Geniposide inhibits interleukin-6 and interleukin-8 production in lipopolysaccharide-induced human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways. Inflamm. Res.: Off. J. Eur. Histamine Res. Soc. … [et al.] 59 (2010), 451–461.
25. Loizzo, M.R., Said, A., Tundis, R., Rashed, K., Statti, G.A., Hufner, A., Menichini, F., Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Phytother. Res.: PTR 21 (2007), 32–36.
26. Maejima, Y., Nobori, K., Ono, Y., Adachi, S., Suzuki, J., Hirao, K., Isobe, M., Ito, H., Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial. Circ. J.: Off. J. Jpn. Circ. Soc. 75 (2011), 589–595.
27. Packer, M., McMurray, J.J.V., Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet 389 (2017), 1831–1840.
28. Park, H.S., Kim, S.H., Kim, Y.S., Ryu, S.Y., Hwang, J.T., Yang, H.J., Kim, G.H., Kwon, D.Y., Kim, M.S., Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation. BioFactors 35 (2009), 373–379.
29. Preiss, D., Campbell, R.T., Murray, H.M., Ford, I., Packard, C.J., Sattar, N., Rahimi, K., Colhoun, H.M., Waters, D.D., LaRosa, J.C., Amarenco, P., Pedersen, T.R., Tikkanen, M.J., Koren, M.J., Poulter, N.R., Sever, P.S., Ridker, P.M., MacFadyen, J.G., Solomon, S.D., Davis, B.R., Simpson, L.M., Nakamura, H., Mizuno, K., Marfisi, R.M., Marchioli, R., Tognoni, G., Athyros, V.G., Ray, K.K., Gotto, A.M., Clearfield, M.B., Downs, J.R., McMurray, J.J., The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur. Heart J. 36 (2015), 1536–1546.
30. Ren, J., Zhang, S., Kovacs, A., Wang, Y., Muslin, A.J., Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 38 (2005), 617–623.
31. Sarafidis, P.A., Georgianos, P.I., Lasaridis, A.N., PPAR-gamma agonism for cardiovascular and renal protection. Cardiovasc. Ther. 29 (2011), 377–384.
32. Sheng, S., Wang, J., Wang, L., Liu, H., Li, P., Liu, M., Long, C., Xie, C., Xie, X., Su, W., Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J. Ethnopharmacol. 154 (2014), 735–744.
33. Shi, Q., Cao, J., Fang, L., Zhao, H., Liu, Z., Ran, J., Zheng, X., Li, X., Zhou, Y., Ge, D., Zhang, H., Wang, L., Ran, Y., Fu, J., Geniposide suppresses LPS-induced nitric oxide, PGE2 and inflammatory cytokine by downregulating NF-kappab, MAPK and AP-1 signaling pathways in macrophages. Int. Immunopharmacol. 20 (2014), 298–306.
34. Soskic, S.S., Dobutovic, B.D., Sudar, E.M., Obradovic, M.M., Nikolic, D.M., Zaric, B.L., Stojanovic, S.D., Stokic, E.J., Mikhailidis, D.P., Isenovic, E.R., Peroxisome proliferator-activated receptors and atherosclerosis. Angiology 62 (2011), 523–534.
35. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., Kuhn, M., Bork, P., Jensen, L.J., von Mering, C., STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43 (2015), D447–452.
36. Tamargo, J., Lopez-Sendon, J., Novel therapeutic targets for the treatment of heart failure. Nat. Rev. Drug Discov. 10 (2011), 536–555.
37. Tang, F., Tang, Q., Tian, Y., Fan, Q., Huang, Y., Tan, X., Network pharmacology-based prediction of the active ingredients and potential targets of Mahuang Fuzi Xixin decoction for application to allergic rhinitis. J. Ethnopharmacol. 176 (2015), 402–412.
38. Tao, W., Xu, X., Wang, X., Li, B., Wang, Y., Li, Y., Yang, L., Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol. 145 (2013), 1–10.
39. Tsai, E.J., Kass, D.A., Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 122 (2009), 216–238.
40. Wang, C.Z., Zhang, Z., Anderson, S., Yuan, C.S., Natural products and chemotherapeutic agents on cancer: prevention vs. treatment. Am. J. Chin. Med. 42 (2014), 1555–1558.
41. Wang, L., Li, Z., Zhao, X., Liu, W., Liu, Y., Yang, J., Li, X., Fan, X., Cheng, Y., A network study of chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway. Evid.-Based Complement. Altern. Med.: eCAM, 2013, 2013, 652373.
42. Wang, L., Zhou, G.B., Liu, P., Song, J.H., Liang, Y., Yan, X.J., Xu, F., Wang, B.S., Mao, J.H., Shen, Z.X., Chen, S.J., Chen, Z., Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 105 (2008), 4826–4831.
43. Wu, L., Wang, Y., Li, Z., Zhang, B., Cheng, Y., Fan, X., Identifying roles of “Jun-Chen-Zuo-Shi” component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology. Chin. Med., 9, 2014, 24.
44. Wu, Z., Ou, L., Wang, C., Yang, L., Wang, P., Liu, H., Xiong, Y., Sun, K., Zhang, R., Zhu, X., Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. Biomed. Pharmacother. = Biomed. Pharmacother. 94 (2017), 1–9.
45. Xiong, D., Deng, Y., Huang, B., Yin, C., Liu, B., Shi, J., Gong, Q., Icariin attenuates cerebral ischemia-reperfusion injury through inhibition of inflammatory response mediated by NF-kappab, PPARalpha and PPARgamma in rats. Int. Immunopharmacol. 30 (2016), 157–162.
46. Xu, J., Song, Z., Guo, Q., Synergistic effect and molecular mechanisms of traditional chinese medicine on regulating tumor microenvironment and cancer cells. BioMed Res. Int., 2016, 2016, 1490738.
47. Zaha, V.G., Young, L.H., AMP-activated protein kinase regulation and biological actions in the heart. Circ. Res. 111 (2012), 800–814.
48. Zhang, H., Ma, S., Feng, Z., Wang, D., Li, C., Cao, Y., Chen, X., Liu, A., Zhu, Z., Zhang, J., Zhang, G., Chai, Y., Wang, L., Xie, X.Q., Cardiovascular disease chemogenomics knowledgebase-guided target identification and drug synergy mechanism study of an herbal formula. Sci. Rep., 6, 2016, 33963.
49. Zhang, H., Zhao, Y., Xia, Z., Du, H., Gao, Y., Xue, D., Zhu, Z., Chai, Y., Metabolic profiles revealed anti-ischemia-reperfusion injury of Yangxinshi tablet in Rats. J. Ethnopharmacol., 2017.
50. Zhang, M., Kass, D.A., Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol. Sci. 32 (2011), 360–365.
51. Zhang, S.J., Liu, Z.H., Zou, C., Wang, L., Effect of metoprolol on sarcoplasmic reticulum Ca2+ leak in a rabbit model of heart failure. Chin. Med. J. 125 (2012), 815–822.
52. Zhou, L., Tang, Y.P., Gao, L., Fan, X.S., Liu, C.M., Wu, D.K., Separation, characterization and dose-effect relationship of the PPARgamma-activating bio-active constituents in the Chinese herb formulation 'San-Ao decoction'. Molecules 14 (2009), 3942–3951.
53. Zhu, J., Li, Z., Zhang, G., Meng, K., Kuang, W., Li, J., Zhou, X., Li, R., Peng, H., Dai, C., Shen, J.K., Gong, F., Xu, Y., Liu, S., Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PloS One, 6, 2011, e23720.
54. Zhu, J., Yi, X., Zhang, J., Chen, S., Wu, Y., Chemical profiling and antioxidant evaluation of Yangxinshi Tablet by HPLC-ESI-Q-TOF-MS/MS combined with DPPH assay. J. Chromatogr. B, Anal. Technol. Biomed. Life Sci. 1060 (2017), 262–271.